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Abstract 
 
 The present study was conducted to evaluate the effect of soybean seeds administration alone or combined with either 
insulin  or  glibenclamide  on  serum  lipid  profiles  in  diabetic  rats.  Male  Wister  rats  were  induced  diabetes  by  a  single 
subcutaneous injection of alloxan 100 mg/kg.b.w.The rats randomly divided into six groups (eight rats in each group): The first 
group served as a control, the second group was administered soybean seed 400 mg/kg.b.w orally as suspension, the third 
group  injected  insulin  10  I.U/kg.b.w,  subcutaneously,  the  fifth  group  administered  glibenclamide  5  mg/kg.b.w.  orally. 
Accompaniment of soybean seeds with either of insulin or glibenclamide given the fourth and sixth groups, using the same 
routes and doses in the individual groups. All treatments were once daily for two weeks. Soybean seeds treatment alone 
resulted in an improvement of body weight and decrease of triglyceride and total lipids levels. While treatment with insulin or 
glibenclamide as alone or combination with soybean seeds showed a significant reduction in the levels of total cholesterol, 
triglyceride, low density lipoprotein, and total lipids, beside a significant increase in both body weight and high density 
lipoprotein. Beneficial effects were seen when soybean seeds combined with either of insulin or glibenclamide treatment. 
These results indicate the usefulness of soybean seeds in the management of diabetes through the hypolipidemic effects of 
soybean seeds in diabetic rats.  
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Introduction 
 
Diabetes mellitus is a chronic metabolic disorder caused 
by  insulin  deficiency,  often  combined  with  insulin 
resistance,  and  it  is  a  major  cause  of  disability  and 
hospitalization and it results in significant financial burden 
(1).  WHO  indicates  that  diabetes  mellitus  is  one  of  the 
major  killers  of  humans  in  our  time  (2).Management  of 
diabetes without any side effect is still a challenge to the 
medical  system,this  has  led to an increasing demand for 
natural products with antidiabetic activity and fewer side 
effects  (3).  Millions  of  people  throughout  the  world 
consume  soy  products,  in  Asian  countries;  soybean  has 
been  stable  for  5000 years (4). Soybean is unique foods 
because  of  their  rich  nutrient  content,  their  complex 
carbohydrate and dietary fiber content contribute to their 
low  glycemic  indexes  which  benefit  diabetic  individuals 
and  reduce  the  risk  of  developing  diabetes  (5).  Previous 
study  indicates  that  protein  of  soybean  decreased 
cholesterol level in rats consume a diet rich in cholesterol 
(6).  Soybean  protein  administration  reduced  cholesterol, 
triglyceride, and Low density lipoprotein levels in healthy 
persons (7) as well as in diabetic patients (8), similar effect 
was also noticed in rats (٩).The present study was designed 
to  investigate  the  effect  of  soybean  seeds  alone  or  in 
combination with insulin or glibenclamide as hypolipidimic 
agent in experimentally diabetic rats.  
 
Materials and methods 
 
Animals: Fifty six male albino rats, 3-4 months old and 
167-218 gm body weight were housed in hanging cages and 
maintained under laboratory controlled of temperature (25 
±2) and light (14 hour light and 10 hour dark), pelleted food 
and tap water were given.  
Induction  of  diabetes:  Rats  were  fasted  for  48  hour 
before inducing diabetes with alloxan (sigma chemical co., 
st,  Lousis,  Mo.USA).  Diabetes  was  induced  by  a  single 
subcutaneous injection of alloxan in a dose of 100 mg/kg of 
body weight (10). Rats were allowed to drink 5% glucose 
solution overnight to prevent drug induced hypoglycemia 
(11). Alloxan treated animals were monitored by periodic 
testing for glucosuria using Lilly Test Tap and ketonuria 
using  chemstrip  MH  5000/k  (Boehrinher,  Mannheim, 
Germany) for four weeks before treatments. 
Experimental  design:  Soybean  seeds  were  purchased 
from  the  local  market  in  Mosul,  and  it's  identify  was 
confirmed  biochemically  in  the  Research  Center  of  the 
college  of  Science,  university  of  Mosul. The seeds were 
powdered before uses. After four weeks of induced diabetes 
the animals were divided into six groups each of 6-8 rats. 
Group 1: Diabetic control rats; Group 2: diabetic rats were 
treated with soybean seeds at a dose of 400 mg/kg.of body 
weight(12);  Group  3:  diabetic  rats  were  treated 
subcutaneously  with  insulin  (Actrapid,  Novo  Nordisk, 
Denmark) at a dose of 10 I.U. /kg of body weight (13); 
Group  5:  diabetic  rats  were  treated  with  glibenclamide 
(Medochemic LTD-Cyprus) at a dose of 5 mg tablet (5 mg 
/kg of body weight) (14), Group 4 and 6; diabetic rats were 
given  soybean  coadminstrated  with  insulin  and 
glibenclamide, respectively at same routes and dose as in 
individual  treatment.  Soybean  seeds  and  glibenclamide 
were given as a suspension orally by gavages needle. All 
treatment was once daily and lasted for two weeks. 
Samples collection: Blood samples were collected from 
the orbital plexus of vein into clean dry centrifuge tubes 
allowed to clot, serum was separated after centrifugation at 
1500 rpm for 15 minuets (15), serum lipid profiles were 
measured using colorimetric assay kits (Bicon, Diagnostic 
Gmbh, Burbach, Germany).  
 Statistical analysis: All data were analyzed by-one-way 
analysis  of  variance,  the  specific  group  differences  were 
determined  using  Duncan  multiple  range  test  (16).  The 
accepted level of significant was P<0.05. 
 
Results 
  
Induced diabetes by alloxan lead after four weeks to a 
significant  increase  in  levels  of  cholesterol,  triglyceride, 
low  density  lipoprotein,  and  total  lipids,  with  decreased 
significantly both body weight and high density lipoprotein 
(Table  1).  Administration  of  soybean  seeds  as  alone 
resulted  in  a  significant  increase  in  body  weight  with  a 
reduction in levels of, triglyceride, low density lipoprotein 
in second week and total lipids in both two weeks (Table 
2).  When  rats  treated  with  insulin  as  alone  or  when 
companied  with  soybean  seeds  resulted  a  significant 
increase in body weight with a reduction in levels of low 
density lipoprotein, and total lipids in both two weeks, with 
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and increased level of high density lipoprotein in the second 
week  only.  Glibenclamide  alone  significantly  increased 
body weight and high density lipoprotein levels in second 
week,  while  causes  reduction  in  cholesterol,  triglyceride, 
low density lipoprotein, and total lipids levels in both two 
weeks (Table 2).  
Combination  of  soybean  seeds  with  glibenclamide 
resulted  an  elevation  of  body  weight  with  reduction  of 
triglyceride level in the second week, and increase level of 
high  density  lipoprotein,  with  reduction  levels  of 
cholesterol, low density lipoprotein, and total lipids in both 
two weeks (Table 2). 
 
Table 1: Comparison between normal and diabetic rats in body weight and lipid profiles. 
Diabetic Rats   Normal Rats    Groups   Parameters 
187 ± 4.5*  201 ± 4.2  Before Treatment  
176 ± 5.3*  204 ± 5.8  1 
168 ± 5.8*  217 ± 8.2  2  After Treatment (weeks) 
Body Weight (gm)  
121.1 ± 3.4*  77.2 ± 2.4  Before Treatment  
122.5 ± 5.5*  78.4 ± 3.5  1 
121.6 ± 5.1*  77.0 ± 3.5  2  After Treatment (weeks) 
Serum Cholesterol level (mg/dl) 
84.9 ± 4.3*  58.8 ± 2.4   Before Treatment  
84.6 ± 3.8*  58.5± 3.9  1 
85.1 ± 3.2*  59.9± 4.7  2  After Treatment (weeks) 
Serum Triglyceride level (mg/dl) 
69.8 ± 3.7*  36.5 ± 2.4  Before Treatment  
72.6 ± 1.9*  38.9 ± 2.7  1 
74.5 ± 1.7*  37.0 ± 3.1  2  After Treatment (weeks) 
Serum HDL level (mg/dl) 
34.3 ± 4.1*  28.9 ± 2.5  Before Treatment  
32.9 ± 1.4*  26.7 ± 2.9  1 
30.1 ± 3.3*  28.0± 2.3  2  After Treatment (weeks)  Serum LDL level (mg/dl) 
863 ± 12*  441 ± 12  Before Treatment  
875 ± 18*  447 ± 12  1 
871 ± 19*  443 ± 12  2 
After Treatment (weeks)  Serum Total lipids level (mg/dl) 
  No. of rats (6-8) in each group, Data is the mean ± SEM, * Significant with normal rats at P < 0.05. 
 
Discussion 
  
In the present study, we have demonstrated that diabetes 
induced  experimentally  by  alloxan  produced significantly 
decreased in body weight, this result agrees with results of 
(17) in rats. The reduction of body weight in diabetic rats is 
due to dehydration and catabolism of fats and proteins (18), 
increased catabolic reaction leading to muscle wasting can 
be the cause of the reduced body weight gain in diabetic 
rats  (19).  Also  the  glucose  can  not  enter  the  cells  when 
there is lack of insulin lead to deficiency of energy for cells 
(20). Induced diabetes lead to increase level of cholesterol, 
(21)  reported  similar  results  in  rats.  The  increase  of 
cholesterol level occurs when there is an absence of insulin 
cause decrease level of Apo-mRNA (22), also deficiency of 
insulin lead to increase cholesterol- acyl- transferase that 
absorbs cholesterol from intestine, leading to increase level 
of cholesterol (23). Triglyceride levels also increased when 
diabetes induced by alloxan, this result agree with result of 
(24)  in  rats.  This  may  be  due  to  deficiency  of  insulin 
causing decrease activity of lipoprotein lipase that convert 
triglyceride to glycerol and fatty acids (25). Low density 
lipoprotein levels also increased, similar result reported by 
(26)  in  rats,  this  is  due  to  increase  synthesis  from 
chylomicron and very low density lipoproteins (27).    
Alloxan induced diabetes lead to increase levels of total 
lipids, this result agrees with result of (28) in rats, increase 
synthesis of very low density lipoproteins and chylomicron 
or decrease removal it from blood may be the causes of 
increase of total lipid levels (29).  
Significant  weight  gain  was  observed  in  soybean 
treatment  and  these  results  are  consistent  with  those  of 
previous study (30) in mice, but our result not agree with 
result of (31) in rats. The possible mechanisms include, that 
soybean contain high percentage of protein, isoflavone, or 
fiber that increase metabolic processes in body (32).Insulin 
treatment  showed  an  increase  of  body  weight,  similar 
observation  has  been  reported  in  diabetic  rats  (33),  but 
disagree with results of (34) in diabetic rats. This effect is 
due  to  its  metabolic  stimulatic  effects  that  decrease 
lipolysis, increase fatty acid synthesis, increase amino acid 
uptake  by  the  tissue,  and  increase  protein  synthesis  (35) 
also  insulin  stimulate  DNA  replication,  modulation  of 
various  enzyme  activities,  through  increase translation  of 
mRNA, and stimulate ribosome to produce protein (36), all 
this  processes  lead  to  improvement  of  body  weight. 
Treatment  with  glibenclamide  leads  to  improvement  of 
body weight, (37) reported similar effects in diabetic rabbit, 
and this result disagree to result of (38) in type 2 diabetic 
patient. Iraqi Journal of Veterinary Sciences, Vol. 23, No. 1, 2009 (17-23)  
 
  20 
 
Table 2: Effect of soybean seeds, insulin, and glibenclamide as alone and combination of soybean with either insulin, or 
glibenclamide on body weight, and serum lipid profiles. 
SerumTriglyceride level 
(mg/dl) 
Serum Cholesterol level 
(mg/dl) 
Weight Body 
g 
After (weeks)  After (weeks)  After (weeks) 
2  1 
Before 
0  2  1 
Before 
0  2  1 
Before 
0 
 
Groups 
 
CD 
85.1 
± 3.2 
CD 
84.6 
± 3.8 
CD 
84.9 ± 
4.3 
C – F 
121.6
±5.1 
C –F 
122.5
±5 
B – F 
121.1±
3.4 
G 
168 
±5 
FG 
176 
±5 
E – F 
187 ± 
4 
Control diabetic 
AB 
69.2 
± 2.8 
BCD 
80.9 
± 2.7 
BCD 
79.9 ± 5 
A – F 
112.7
±5.4 
B – F 
120.4
±6.6 
EF 
124.6±
5.2 
B – F 
192 ± 
4 
D – G 
183 ± 
7 
EFG 
181 ± 
4 
Soybean seeds 400 mg/kg.b.w. 
A 
56.6 
± 2.6 
BC 
75.3 
± 2.2 
CD 
86.1 ± 
2.4 
A 
102± 
4.8 
A – E 
112.8
±3.2 
EF 
125.5±
2.4 
ABC 
202 ± 
6 
A – E 
198 ± 
6 
A – E 
195 ± 
5 
Insulin 10 I.U./Kg.b.w 
A 
54.3 
± 4.5 
BC 
75.6 
± 2.4 
BCD 
81.7 ± 
2.9 
AB 
107.7
± 
3.7 
ABC 
109.3
±1.9 
B – F 
121.1±
2.3 
AB 
208 ± 
4 
A – D 
200 ± 
6 
D – G 
184 ± 
4 
Soybean seeds 400mg/kg.b.w + 
Insulin 10 I.U./Kg.b.w. 
BC 
71.5± 
3.4 
BC 
78.1 
± 4.7 
D 
91.1± 
3.9 
A 
106.5
± 
3.8 
AB 
108.3
±3.6 
DEF 
123.5±
2.9 
B – F 
192 ± 
4 
C – F 
189 ± 
6 
D –G 
184 ± 
4 
Glibenclamide 5mg/kg.b.w 
 
B 
74.3 
± 2.5 
BCD 
80.5 
± 3.6 
CD 
83.5 ± 
3.8 
A 
105.3
±3.7 
A – D 
110.7
±2.6 
F 
125.9±
2.6 
A 
210± 
4 
C – F 
190± 
5 
B – F 
191 ± 
5 
Glibenclamide 5mg/kg.b.w + 
Soybean seeds 400 mg/kg.b.w 
Serum Total lipids level 
(mg/dl) 
Serum LDL 
level (mg/dl) 
Serum HDL 
level (mg/dl) 
After (weeks)  After (weeks)  After (weeks) 
2  1 
Before 
0  2  1 
Before 
0  2  1 
Before 
0 
 
Groups 
 
F 
871 ± 
19 
F 
875 ± 
18 
F 
863 ± 12 
DE 
30.1 
± 3.3 
EF 
32.9 
± 1.4 
EFG 
34.3 ± 
4.1 
BCD 
74.5± 
1.7 
CDE 
72.6 
± 1.9 
CDE 
69.8 ± 
3 
Control diabetic 
D 
701 ± 
17 
E 
796 ± 
15 
F 
856 ± 16 
CD 
25± 
1.9 
FG 
40.6 
± 2.4 
FG 
42.1 ± 
3.4 
CDE 
69.8 
± 2.9 
E 
63.6 
± 3.2 
DE 
66.5 ± 
2.8 
Soybean seeds 400 mg/kg.b.w . 
D 
659± 
11 
E 
775 ± 
16 
F 
859 ± 17 
AB 
14 ± 
0.5 
BCD 
22.3 
± 2.8 
FG 
40.9 ± 
6 
AB 
81.6 
± 3.2 
CDE 
72.4 
± 3.6 
DE 
67.4 ± 
4 
Insulin 10 I.U./Kg.b.w 
A 
382 ± 
21 
D 
604 ± 
12 
F 
867 ± 29 
A 
4.9 ± 
0.7 
BC 
20 ± 
3.5 
EFG 
36.5 ± 
3.1 
AB 
83.2 
± 2.1 
ABC 
77 ± 
2.9 
CDE 
68.2 ± 
2.8 
Soybean seeds 400mg/kg.b.w + 
Insulin 10 I.U./Kg.b.w . 
E 
776 ± 
11 
E 
788 ± 
12 
F 
854 ± 18 
A 
9.7 ± 
1.7 
BCD 
21.1 
± 1.6 
G 
43 ± 3 
AB 
80.5 
± 2.9 
CDE 
71.5 
± 3 
E 
63.8 ± 
2.5 
Glibenclamide 5mg/kg.b.w 
 
B 
433 ± 
13 
D 
679 ± 
12 
F 
867 ± 16 
A 
5.9 ± 
0.8 
B 
18.3 
± 3.1 
G 
42.9 ± 
4.6 
A 
84.6 
± 2.5 
BCD 
74.7 
± 1.8 
E 
64.7 ± 
3.3 
Glibenclamide 5mg/kg.b.w + 
Soybean seeds 400 mg/kg.b.w 
No. of rats (6-8) in each group, Data is the mean ± SEM,  
Different letters indicate significant differences between groups horizontally and vertically at P < 0.05. Iraqi Journal of Veterinary Sciences, Vol. 23, No. 1, 2009 (17-23)  
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      Glibenclamide have an action like insulin so increasing 
the glucose translator and increase metabolism of it (39).  
Earlier  study  has  shown  that  cholesterol  level  was 
decreased in mice treated with soybean seeds by (40), and 
this  has  not  confirmed  in  present  study.  Therefore,  we 
believed that 15 days would not provide adequate exposure 
to  have  an  effect.  Treatment  with  insulin  significantly 
decreased  cholesterol  level,  previous  studies  by  (41)  in 
diabetic rats, showed same results. Alternatively, inhibition 
of acylcoenzyme of cholesterol acyl transferase in intestine 
that’s absorbing cholesterol from intestine may play a role 
in observed lowering of serum cholesterol level (23), also 
insulin increase or stimulate synthesis of ApoE mRNA that 
leads to decrease level of cholesterol (42). Glibenclamide 
significantly  decreased  cholesterol  levels,  (43)  reported 
similar result in type 2 diabetic patient, but not similar to 
result of (44) in type 2 diabetic patient, the glibenclamide 
reduce  lipolysis  that  stimulated  by  isoproterenol  lead  to 
decrease liberate free fatty acids and cholesterol in blood 
(45),  also  decrease  of  free  fatty  acids  leads  to  decease 
cholesterol level (46).  
From  the  results  soybean  seeds  reduced  triglyceride 
level significantly, this result is in agreement with studies 
of (47) in diabetic rats, while (48) reported different result 
on  postmenopausal  women.  Possible  explanations  for 
lowering triglyceride level include that soybean’s content of 
isoflavones serve  as  a  natural  selective  estrogen  receptor 
modulator that exert an effect on lipid metabolism through 
their biological similarities to estrogen-receptor-dependent 
gene expressions. (49). or isoflavones affect in cellular lipid 
homeostasis  by  the  down-regulation  of  sterol-regulatory-
element-binding-protein  (SREBP)  and  its  target  genes  in 
the liver which are involved in the synthesis of triglyceride 
(50).  Insulin  treatment  decreased  triglyceride  levels,  a 
similar  result  reported  by  (36)  in  alloxan  diabetic  rats, 
insulin  stimulate  lipogenesis  so  increases  level  of 
triglyceride in fatty tissues and decreases its level in serum 
(51).Treatment  with  glibenclamide  decrease  triglyceride 
level, this result agree with (52) in type 2 diabetic patient, 
while  (53)  reported  different  result  in  type  2  diabetic 
patient. The reduction of triglyceride may be due to that 
glibenclamide  is  capable  of  exerting  direct  insulin  like 
effect (54). 
High  density  lipoprotein  increased  significantly  in 
insulin treated rats; these result agreements with results of 
(55)  in  streptozotocin-induced  diabetes  rats,  the  insulin 
stimulate  production  and  secret  high  density  lipoprotein 
from  intestine  (56).  Glibenclamide  increase  high  density 
lipoprotein level, because it can act as insulin like effect as 
describe above.  
Our  study  showed  that  rats  treated  with  soybean 
resulted  in  reduction  in  low  density  lipoprotein  levels; 
similar  decreases  was  described  previously  in  rats  and 
hamster (57), our results disagreement with (58) in rabbit. 
This  decrease  duo  to  the  fatty  acids  content  of  soybean 
increase activity of receptors of low density lipoproteins on 
adipose  cells  (25).  Insulin  treatment  produced  significant 
decrease  in  low  density  lipoprotein  levels;  similar 
observation  was  reported  by  (24)  in  diabetic  rats.  The 
increase number of receptors on monocyte cells by insulin 
leading to increase removal of low density lipoprotein from 
blood (59).Treatment of rats with glibenclamide produce a 
significant decrease of low density lipoprotein levels, also 
(55) reported similar results in type 2 diabetic patients, but 
disagreement with (60), in type 2 patient.  
Total  lipids  levels  decreased  when  rats  treated  with 
either  of  soybean,  or  insulin,  or  glibenclamide,  as  alone, 
This  may  be  due  to  reduction  in  levels  of  cholesterol, 
triglyceride,  low  density  lipoprotein,  leading  to  decrease 
levels of total lipids because they are the total amount of 
lipids in blood at constant percentage (27).  
When  there  are  a  combination  treatment  of  soybean 
with  either  insulin  or  glibenclamide  the  improvement  of 
body weight and increase of high density lipoprotein level, 
also  reduction  of  cholesterol,  triglyceride,  low  density 
lipoprotein and total lipids levels become better than rats 
treated  with  soybean,  insulin,  or  glibenclamide  as  alone. 
This due to synergism of activity of soybean with activity 
of either insulin or glibenclamide.  
The results of the present investigation clearly indicate 
that soybean seeds in a dose of 400 mg/kg of body weight 
found to be effective as antidiabetic through managing the 
complications associated with diabetes such as body weight 
maintenance  and  hyperlipidaemia,  also  our  results 
suggested that combinations of soybean seeds with either 
insulin or glibenclamide increased antidiabetic activity  
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